KSG 504

has superior selectivity and affinity to CCK-A receptors; derived from proglumide

Also Known As:

4-N-(3-methoxypropyl)-N-pentylcarbamoyl-5-(2-naphthylsulfonyl)pentanoic acid; KSG-504; L-Arginine, mono((R)-5-((3-methoxypropyl)pentylamino)-4-((2-naphthalenylsulfonyl)methyl)-5-oxopentanoate)

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Pancreatitis 12/01/1993 - "The inhibition of evolution of pancreatitis was demonstrated histologically in KSG-504 treated rats. " 04/01/1996 - "Moreover, KSG-504 (50 and 100 mg/kg, i.v., x 2) mitigated the histological changes of taurocholate-induced acute pancreatitis. " 04/01/1996 - "[Effect of KSG-504, a new CCK-A-receptor antagonist, on experimental acute pancreatitis in rats and mice]." 08/01/1995 - "Effects of short-term administration of the CCK receptor antagonist, KSG-504, on regeneration of pancreatic acinar cells in acute pancreatitis in rats." 07/01/1994 - "We investigated the effect of a new cholecystokinin receptor antagonist, KSG 504, on the healing process in edematous and hemorrhagic acute pancreatitis after releasing the loop. "
2.	Vomiting 01/01/1996 - "KSG-504 did not affect the general behavior of dogs up to the dose of 30 mg/kg, but the drug (100 mg/kg, i.v.) caused vomiting in 3 out of the 5 dogs. "
3.	Ascites 04/01/1996 - "KSG-504 administered immediately and 1.5 hr after sodium-taurocholate injection at 100 mg/kg reduced the increases of pancreatic enzymes in the plasma, pancreatic wet weight and ascites. "

Related Drugs and Biologics

1.	Cholecystokinin Receptors (Cholecystokinin Receptor)
2.	Therapeutic Uses
3.	Cholecystokinin A Receptor
4.	Lipase (Acid Lipase)
5.	Ethionine
6.	Amylases
7.	Cytokines
8.	Taurocholic Acid (Sodium Taurocholate)
9.	Enzymes
10.	Cholecystokinin (Pancreozymin)